JY
DNLI icon

Jeff Yass’s Denali Therapeutics DNLI Stock Holding History

Jeff Yass’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.21M Sell
85,800
-44,300
-34% -$910K ﹤0.01% 6265
2026
Q1 		$2.5M Buy
130,100
+96,100
+283% +$1.91M ﹤0.01% 5652
2025
Q4 		$561K Sell
34,000
-40,500
-54% -$684K ﹤0.01% 8497
2025
Q3 		$1.08M Buy
74,500
+36,100
+94% +$519K ﹤0.01% 7176
2025
Q2 		$537K Buy
+38,400
New +$540K ﹤0.01% 9013
2025
Q1 		– Sell
-13,700
Closed -$279K – 12669
2024
Q4 		$279K Buy
13,700
+500
+4% +$12.8K ﹤0.01% 9987
2024
Q3 		$385K Buy
13,200
+700
+6% +$17.4K ﹤0.01% 9075
2024
Q2 		$290K Sell
12,500
-5,900
-32% -$113K ﹤0.01% 9515
2024
Q1 		$378K Buy
18,400
+7,900
+75% +$148K ﹤0.01% 9159
2023
Q4 		$225K Sell
10,500
-6,500
-38% -$129K ﹤0.01% 10432
2023
Q3 		$351K Buy
17,000
+8,800
+107% +$223K ﹤0.01% 9019
2023
Q2 		$242K Sell
8,200
-6,900
-46% -$194K ﹤0.01% 9879
2023
Q1 		$348K Sell
15,100
-13,300
-47% -$366K ﹤0.01% 9403
2022
Q4 		$790K Sell
28,400
-16,900
-37% -$503K ﹤0.01% 6705
2022
Q3 		$1.39M Buy
45,300
+22,400
+98% +$728K ﹤0.01% 5767
2022
Q2 		$674K Buy
22,900
+8,200
+56% +$215K ﹤0.01% 7527
2022
Q1 		$473K Buy
14,700
+400
+3% +$13.8K ﹤0.01% 9135
2021
Q4 		$638K Sell
14,300
-27,100
-65% -$1.28M ﹤0.01% 8498
2021
Q3 		$2.09M Buy
41,400
+7,100
+21% +$400K ﹤0.01% 5736
2021
Q2 		$2.69M Sell
34,300
-7,700
-18% -$476K ﹤0.01% 5269
2021
Q1 		$2.4M Sell
42,000
-105,100
-71% -$7.04M ﹤0.01% 5470
2020
Q4 		$12.3M Buy
147,100
+126,600
+618% +$7.65M ﹤0.01% 2258
2020
Q3 		$735K Sell
20,500
-13,400
-40% -$404K ﹤0.01% 6858
2020
Q2 		$820K Buy
+33,900
New +$797K ﹤0.01% 6339
2020
Q1 		– Sell
-37,900
Closed -$660K – 10348
2019
Q4 		$660K Sell
37,900
-17,500
-32% -$291K ﹤0.01% 6385
2019
Q3 		$849K Buy
55,400
+5,800
+12% +$111K ﹤0.01% 6059
2019
Q2 		$1.03M Buy
+49,600
New +$1.11M ﹤0.01% 5585

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
California State Teachers Retirement System (CalSTRS)
California State Teachers Retirement System (CalSTRS) West Sacramento, California $782B AUM 28.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Jeff Yass's DNLI Position: Q2 2026 in Review

Jeff Yass increased its Denali Therapeutics (DNLI) stake by 144% in Q2 2026, buying an estimated $1.5M and bringing the position to 123,258 shares worth $3.17M. The position accounts for ﹤0.01% of the portfolio, ranked #5514.

Jeff Yass first reported a position in DNLI in Q2 2019 and has held it in 28 quarters since. The position peaked at $7.85M in Q1 2023. 291 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • Jeff Yass held 123,258 shares of Denali Therapeutics worth $3.17M as of Q2 2026.
  • Jeff Yass bought 72,783 Denali Therapeutics shares in Q2 2026, an estimated $1.5M.
  • Denali Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #5514 holding.
  • Jeff Yass first reported a position in Denali Therapeutics in Q2 2019 and has held it in 28 quarters since.
  • Jeff Yass's Denali Therapeutics position peaked at $7.85M in Q1 2023.
  • 291 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.